GenSight Biologics Lists On Euronext To Become Europe's First Listed Gene Therapy Company - €40 Million Raised; Market Capitalisation €149 Million

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs), today welcomed GenSight Biologics, a biopharmaceutical specialist in gene therapy,  for its first day of trading on compartment C of Euronext’s regulated market in Paris.